BioEclipse Therapeutics
Blood & Organ Banks · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
319 Bernardo Ave, Mountain View, Califor...Phone Number
(408) 809-1030Website
www.bioeclipse.comRevenue
$5.8 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
2
About BioEclipse Therapeutics
BioEclipse Therapeutics is a pioneering company focused on developing next-generation immunotherapies aimed at treating advanced cancer patients with limited options. Their proprietary allogeneic technology is designed to harness the power of both innate and adaptive immunity to effectively target and destroy solid tumors, which account for 90% of all cancers. With innovative therapies like CRX200 and CRX100, they aim to provide low-cost, engineered immune solutions that demonstrate significant potency against various tumor types. The company's mission is to eradicate primary disease while fostering a lasting tumor-specific immune response in patients facing resistant and recurring solid tumors.Explore more
BioEclipse Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioEclipse Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioEclipse Therapeutics has recently received funding, and reach out quickly before it becomes old news!
BioEclipse Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioEclipse Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at BioEclipse Therapeutics
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on BioEclipse Therapeutics recently announced quarterly report
Check out if BioEclipse Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once BioEclipse Therapeutics has new funding data
Click to see if BioEclipse Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined BioEclipse Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to BioEclipse Therapeutics
Compare insights from companies similar to BioEclipse Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioEclipse Therapeutics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
BioEclipse Therapeutics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about BioEclipse Therapeutics.
BioEclipse Therapeutics financials insights
Gather financial insights about BioEclipse Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Other Financing Round
$7.7M
BioEclipse Therapeutics Tech Stack
A closer look at the technologies used by BioEclipse Therapeutics
See more technologies
BioEclipse Therapeutics News & Media
BioEclipse Therapeutics Appoints New Board Member and Names Interim CFO
MOUNTAIN VIEW, Calif., Jan. 26, 2022 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the appointment of Mahmoud Mahmoudian, Ph.D.,...BioEclipse Therapeutics™ to Present at Virtual H.C. Wainwright 23rd Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 10, 2021 /PRNewswire/ -- BioEclipse Therapeutic™, a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on its patented natural killer T-cell (NKT)/oncolytic virus technology platform, announced today that Pamela Reilly...BioEclipse Therapeutics™ to Present at the Spring 2021 Virtual Oncology Investor Conference
MOUNTAIN VIEW, Calif., March 29, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today that Pam Contag, Ph.D., President and Chief...BioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid Tumors
Mountain View, Calif., March 5, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the administration of the first dose of CRX100...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioEclipse Therapeutics
Sign Up For FreeTo access detailed company insights
BioEclipse Therapeutics is a pioneering company focused on developing next-generation immunotherapies aimed at treating advanced cancer patients with limited options. Their proprietary allogeneic technology is designed to harness the power of both innate and adaptive immunity to effectively target and destroy solid tumors, which account for 90% of... Read More
